Kiniksa Pharmaceuticals International, plc filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company incorporated in England and Wales. Form 8-K reports cover operating results and financial condition, ARCALYST portfolio execution, investor presentations, and executive appointments or consulting arrangements.
Proxy materials cover annual meeting matters, director elections, executive compensation, shareholder voting procedures, and board governance. The filing record also identifies the company’s Class A ordinary shares, Nasdaq Global Select Market listing, and recurring disclosures tied to its commercial ARCALYST franchise and cardiovascular-focused development portfolio.
Kiniksa Pharmaceuticals International, plc reported higher profitability for the three and six months ended June 30, 2026, driven by growth in ARCALYST. Product revenue, net was $243,600 for the quarter, up from $156,797 a year earlier, and $457,866 for the first half of 2026 versus $294,582 in 2025. Quarterly net income was $25,432 and first-half net income was $48,024, with diluted net income per share of $0.30 and $0.58, respectively.
As of June 30, 2026, cash and cash equivalents were $175,677 and short-term investments were $350,251, contributing to total assets of $896,110 and shareholders’ equity of $654,149. Management states that existing cash, cash equivalents and short-term investments, together with expected cash inflows from operations, are expected to fund operating expenses and capital expenditure requirements for at least the next 12 months. The company continues to advance its pipeline, including KPL-387, now in a pivotal Phase 3 recurrent pericarditis trial with expected commercialization in 2028 or 2029, and KPL-1161, for which a Phase 1 trial is planned by the end of 2026, while it has discontinued abiprubart development in Sjogren's Disease and is exploring strategic alternatives for that asset.
Kiniksa Pharmaceuticals International reported second quarter 2026 results highlighted by strong growth in its flagship therapy ARCALYST. ARCALYST net product revenue was $243.6 million in Q2 2026, representing approximately 55% year-over-year growth, and management increased 2026 ARCALYST net product revenue guidance to $980–$995 million. The company noted continued growth in new and repeat prescribers and stated that about 21% of approximately 14,000 multiple-recurrence pericarditis patients were actively on ARCALYST at quarter-end.
Total revenue for Q2 2026 was $243.6 million, generating income from operations of $27.2 million and net income of $25.4 million, or $0.30 diluted EPS. For the first six months of 2026, revenue reached $457.9 million with net income of $48.0 million. Cash, cash equivalents, and short-term investments totaled $525.9 million as of June 30, 2026, with shareholders’ equity of $654.1 million. Kiniksa highlighted clinical progress, including Phase 3 enrollment for KPL-387 in recurrent pericarditis and ongoing preclinical development of KPL-1161, and stated an expectation that its current operating plan will remain cash flow positive on an annual basis.
Kiniksa Pharmaceuticals International, plc reported that its chief strategy officer, Dhiraj H. Malkani, received several equity awards on July 1, 2026. These include performance share units, performance share options and restricted share units, each linked to Class A Ordinary Shares.
The grants comprise 1,307 and 1,245 Performance Share Units, 2,188 and 2,119 Performance Share Options with a $62.88 exercise price, 14,000 Restricted Share Units, and 82,600 Share Options also at $62.88 per share. The options expiring on June 30, 2036 generally vest over time or upon specific milestones.
Footnotes explain that RSUs vest in annual installments starting July 1, 2026, while Performance Share Units and Performance Share Options vest only if Kiniksa submits a biologics license application for KPL-387 for recurrent pericarditis and, for certain awards, if the FDA approves its commercial sale and marketing in the United States.
Kiniksa Pharmaceuticals International, plc filed an initial Form 3 for Dhiraj H. Malkani, who serves as Chief Strategy Officer. This filing identifies him as a reporting insider under SEC rules but does not describe any specific share transactions or option exercises.
Kiniksa Pharmaceuticals International, plc director Barry D. Quart reported compensation-related equity activity. He exercised vested Restricted Share Units (RSUs) into 2,799 Class A Ordinary Shares, bringing his directly held Class A Ordinary Shares to 15,345.
Quart also received new equity awards on May 29, 2026. He was granted 2,026 RSUs, each representing one Class A Ordinary Share, which vest in full on the earlier of the first anniversary of the grant date or the company’s next annual shareholder meeting. In addition, he received options for 12,158 Class A Ordinary Shares at an exercise price of $48.38, vesting in twelve substantially equal monthly installments over roughly one year.
Kiniksa Pharmaceuticals International, plc director Kimberly J. Popovits reported routine equity compensation transactions. On May 29, 2026, she exercised 2,799 Restricted Share Units into an equal number of Class A Ordinary Shares, bringing her direct Class A Ordinary Share holdings to 15,345 shares after the transaction.
On the same date, she received new awards of 2,026 Restricted Share Units and a share option for 12,158 Class A Ordinary Shares at an exercise price of $48.38 per share. The option vests in twelve substantially equal monthly installments starting from the May 29, 2026 grant date, and the RSUs vest in full on the earlier of the first anniversary of the grant or the next annual shareholder meeting.
Kiniksa Pharmaceuticals International, plc reported that trusts associated with Chairman and CEO Sanj K. Patel adjusted their holdings of ordinary shares. The Anglia 2013 Revocable Trust converted 900,000 Class B Ordinary Shares into 900,000 Class A Ordinary Shares at a stated price of $0.00 per share, a non-cash derivative conversion rather than a market trade.
After this conversion, the Anglia 2013 Revocable Trust holds 951,794 Class A Ordinary Shares and 626,160 Class B Ordinary Shares. Separate family trusts report indirect holdings of 76,174 and 109,795 Class A Ordinary Shares. The filing reflects changes in share classes held through family trusts, not open-market buying or selling.
Kiniksa Pharmaceuticals International, plc director Tracey L. McCain reported routine equity compensation activity. McCain exercised 2,799 Restricted Share Units (RSUs) into 2,799 Class A Ordinary Shares, bringing direct holdings in the shares to 15,345. The filing also shows a new grant of 2,026 RSUs and a separate grant of share options for 12,158 Class A Ordinary Shares at an exercise price of $48.38 per share. The option vests in twelve substantially equal monthly installments following the May 29, 2026 grant date, while the new RSUs vest in full on the earlier of the first anniversary of the grant date or the next annual shareholder meeting.
Kiniksa Pharmaceuticals director Thomas Malley reported equity compensation transactions and updated holdings. On May 29, 2026, he exercised 2,799 Restricted Share Units, receiving the same number of Class A Ordinary Shares at a stated price of $0.00 per share.
On the same date, he received a new grant of 2,026 Restricted Share Units and a share option for 12,158 Class A Ordinary Shares with an exercise price of $48.38 per share. The option vests in twelve substantially equal monthly installments following the grant date, with the final installment vesting on the earlier of the first anniversary of the grant or the issuer’s next annual meeting of shareholders.
Following these transactions, Malley directly holds 15,345 Class A Ordinary Shares. An additional 71,967 Class A Ordinary Shares are held indirectly through Mossrock Capital, LLC, where he serves as president and may be deemed to beneficially own those shares.
Kiniksa Pharmaceuticals International, plc director Richard S. Levy reported routine equity compensation activity. He exercised 2,799 Restricted Share Units, receiving the same number of Class A Ordinary Shares, bringing his direct holdings in that class to 21,956 shares.
On the same date, he received new grants of 2,026 Restricted Share Units and a share option covering 12,158 Class A Ordinary Shares at an exercise price of $48.38 per share. Footnotes state the option vests in twelve substantially equal monthly installments over roughly one year, while the new RSUs vest in full on the earlier of the grant anniversary or the company’s next annual shareholder meeting.